GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PharmaRoth Labs Inc (GREY:ROTH) » Definitions » Intrinsic Value: Projected FCF

PharmaRoth Labs (PharmaRoth Labs) Intrinsic Value: Projected FCF : $0.00 (As of May. 21, 2024)


View and export this data going back to 2008. Start your Free Trial

What is PharmaRoth Labs Intrinsic Value: Projected FCF?

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company. The details of how we calculate the intrinsic value of stocks are described in detail here.

As of today (2024-05-21), PharmaRoth Labs's Intrinsic Value: Projected FCF is $0.00. The stock price of PharmaRoth Labs is $0.0001. Therefore, PharmaRoth Labs's Price-to-Intrinsic-Value-Projected-FCF of today is 0.0.

The historical rank and industry rank for PharmaRoth Labs's Intrinsic Value: Projected FCF or its related term are showing as below:

ROTH's Price-to-Projected-FCF is not ranked *
in the Biotechnology industry.
Industry Median: 2.35
* Ranked among companies with meaningful Price-to-Projected-FCF only.

PharmaRoth Labs Intrinsic Value: Projected FCF Historical Data

The historical data trend for PharmaRoth Labs's Intrinsic Value: Projected FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PharmaRoth Labs Intrinsic Value: Projected FCF Chart

PharmaRoth Labs Annual Data
Trend Jun08 Jun09 Jun10
Intrinsic Value: Projected FCF
- - -

PharmaRoth Labs Quarterly Data
Mar07 Sep07 Dec07 Mar08 Jun08 Sep08 Dec08 Mar09 Jun09 Sep09 Dec09 Mar10 Jun10 Sep10 Dec10 Mar11
Intrinsic Value: Projected FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of PharmaRoth Labs's Intrinsic Value: Projected FCF

For the Biotechnology subindustry, PharmaRoth Labs's Price-to-Projected-FCF, along with its competitors' market caps and Price-to-Projected-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PharmaRoth Labs's Price-to-Projected-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PharmaRoth Labs's Price-to-Projected-FCF distribution charts can be found below:

* The bar in red indicates where PharmaRoth Labs's Price-to-Projected-FCF falls into.



PharmaRoth Labs Intrinsic Value: Projected FCF Calculation

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company.

The details of how we calculate the intrinsic value of stocks are described in detail here.

This method smooths out the free cash flow over the past 6-7 years, multiplies the results by a growth multiple, and adds a portion of Total Stockholders Equity.

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + 0.8 * Total Stockholders Equity (most recent) ) / Shares Outstanding (Diluted Average)

In the case of negative Total Stockholders Equity, the following formula is used (see Explanation section below for the reason):

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + Total Stockholders Equity (most recent) / 0.8 ) / Shares Outstanding (Diluted Average)



PharmaRoth Labs  (GREY:ROTH) Intrinsic Value: Projected FCF Explanation

The growth multiple is capped between 8.35 and 17.74.

Total Stockholders Equity weighting is more art than science and it should always be revisited in more detail when researching a company. Weightings from 0% to 100% to more than 100% are possible. 80% was chosen as a happy median after taking the above ideas into consideration.

PharmaRoth Labs's Price-to-Intrinsic-Value-Projected-FCF for today is calculated as

Price-to-Intrinsic-Value-Projected-FCF=Share Price/Intrinsic Value: Projected FCF
=0.0001/
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


PharmaRoth Labs Intrinsic Value: Projected FCF Related Terms

Thank you for viewing the detailed overview of PharmaRoth Labs's Intrinsic Value: Projected FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


PharmaRoth Labs (PharmaRoth Labs) Business Description

Traded in Other Exchanges
N/A
Address
8250 West Charleston Boulevard, Suite 110, Las Vegas, NV, USA, 89117
PharmaRoth Labs Inc is engaged in the manufacture and sale of a treatment for Type II diabetes called Sucanon. The company also does marketing and selling of nutraceutical drugs.

PharmaRoth Labs (PharmaRoth Labs) Headlines